For Q1 FY2026 ended March 31, 2026, ANI Pharmaceuticals reported revenue of $237.5 million, up 20.5% year-over-year. Net income surged 88.1% to $29.5 million, with diluted EPS of $1.28, an 85.5% increase. Operating income rose 48.5% to $38.9 million. The company held $311.2 million in cash, $562.3 million in equity, and $286.0 million in long-term debt.
•Revenue increased 20.5% YoY to $237.5 million.
•Net income rose 88.1% to $29.5 million; diluted EPS up 85.5% to $1.28.
•Operating income grew 48.5% to $38.9 million.
•Cash and equivalents: $311.2 million; long-term debt: $286.0 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
ANI Pharmaceuticals, Inc., a biopharmaceutical company develops, manufactures, and markets branded and generic pharmaceutical products in the United States and globally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. Incorporated in 2001, ANI Pharmaceuticals is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets both branded and generic pharmaceutical products. Its product portfolio includes injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. The company also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. ANI serves its products to a wide range of customers, including national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. The company operates primarily in the United States and also has a global presence.
Where is ANI Pharmaceuticals listed and in which currency?
ANI Pharmaceuticals, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ANIP. The company's stock is traded in US Dollars (USD), which is the official currency of the United States. Investors can buy and sell shares of ANI Pharmaceuticals on the Nasdaq exchange, and all financial reporting and transactions are conducted in USD.
What sector and industry does ANI Pharmaceuticals belong to?
ANI Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the development, production, and marketing of pharmaceutical products, with a focus on both branded and generic drugs. As a specialty and generic drug manufacturer, ANI produces a variety of medications that are either off-patent (generics) or branded specialty products, often targeting specific therapeutic areas.
Where is ANI Pharmaceuticals headquartered and what markets does it serve?
ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota, United States. The company was incorporated in 2001 and primarily serves the United States market, but also has a global presence. Its products are distributed to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. This broad distribution network allows ANI to reach a wide range of customers across the healthcare system.
What are the main products and business model of ANI Pharmaceuticals?
ANI Pharmaceuticals develops, manufactures, and markets both branded and generic pharmaceutical products. Key products include injectables, softgel capsules, Cortrophin gel, and the ILUVIEN and YUTIQ products. The company also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. ANI's business model involves selling these products to various healthcare customers such as wholesalers, pharmacies, hospitals, and group purchasing organizations. By offering a diverse portfolio of both branded and generic drugs, the company generates revenue from multiple segments of the pharmaceutical market.